Oncternal therapeutics, inc. (GTXI)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities
Net loss

-4,738

-4,156

-4,892

-22,846

-2,294

-5,415

-9,431

-10,015

-13,557

-9,277

-8,504

-6,405

-6,253

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,106

-

34,866

-47,952

-2,384

-14,545

-4,935

-10,944

-8,987

-7,790

-8,937

-12,802

-12,582

-10,715

5,101

-10,381

-11,080

-10,682

-9,344

-10,673

-2,595

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

399

315

90

63

39

520

441

590

646

926

903

659

663

639

819

785

714

752

727

722

419

242

235

1,736

2,215

1,506

731

682

814

770

753

243

882

1,048

1,081

898

1,199

Depreciation and amortization

-

-

-

-

-

12

11

12

11

12

12

11

12

11

8

5

4

7

7

12

17

16

21

32

33

51

71

112

150

154

183

203

210

221

233

268

318

Change in fair value of preferred stock warrants liability

-

0

0

1,285

-17

-

-

-

-

-

-

-

-

0

0

0

-8,163

-2,729

-40,720

43,016

-2,648

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash lease expense

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Directors' deferred compensation

-

-

-

-

-

42

41

41

42

42

41

42

41

40

33

29

30

28

27

27

31

31

31

31

32

30

31

32

42

41

40

43

45

-

-

-

-

Deferred revenue amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

8,066

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,598

Changes in operating assets and liabilities:
Directors' deferred compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

45

51

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-74

224

-3

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55

-21

-7

Prepaid and other assets

-90

-224

-395

821

-158

679

207

-203

-111

129

-81

-110

-189

333

32

-231

-338

-536

899

1,252

-157

-102

-383

-107

1,169

-549

-244

-519

913

-1,751

125

-446

215

373

273

-585

788

Accounts payable

336

-360

33

-2,013

-2,422

158

1,648

-266

-865

153

1,848

89

-706

-3

-164

484

521

198

-613

359

-74

333

-813

373

-189

-445

-543

696

-607

500

-255

525

-282

390

-310

481

-190

Accrued expenses and other liabilities

-

-

-

-

-

-4,253

-220

-1,467

2,500

-1,457

2,246

339

852

1,250

-2

27

-325

-763

1,631

-94

-213

-341

-637

-1,231

-22

-186

-2,637

-596

-827

-2,566

4,534

987

-70

-

-

-

-

Accrued liabilities

455

300

-52

-1,767

264

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

647

1,181

-766

Change in operation lease liability

-36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

-578

632

621

1,748

639

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-4,036

-3,045

-3,829

-6,239

-3,633

-9,615

-7,717

-10,902

-11,112

-9,730

-3,373

-5,155

-5,202

-5,260

-6,252

-4,491

-4,775

-5,204

-4,974

-5,162

-4,695

-5,061

-5,715

-9,896

-8,087

-7,651

-11,040

-11,357

-13,923

-10,065

-8,600

-7,934

-10,510

-8,540

-7,902

-7,418

-9,229

Cash flows from investing activities
Acquisition related costs paid

-

0

1,604

472

79

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

82

0

8

-

-

-

-

0

1

0

4

0

0

3

29

-

-

-

-

9

5

24

16

Purchase of short-term investments, held to maturity

-

-

-

-

-

0

10,044

29,005

5,106

27,883

200

6,000

5,200

13,004

5,200

10,000

7,200

15,000

10,006

20,011

10,202

31,415

1,225

4,120

5,145

200

0

0

1,225

-

-

-

-

-

-

-

-

Purchase of short-term investments, held to maturity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,770

1,960

-

4,365

1,960

6,125

Proceeds from maturities of short-term investments, held to maturity

-

-

-

-

-

14,784

24,265

16,986

16,003

0

6,200

8,540

9,419

5,245

10,200

12,000

10,200

22,463

12,454

25,337

11,180

-

-

-

-

1,675

1,715

2,695

3,185

4,675

3,140

2,205

4,610

-

-

-

-

Net cash used in investing activities

-

0

-1,604

17,820

-79

14,784

14,221

-12,019

10,897

-27,885

6,000

2,540

4,219

-7,759

4,918

2,000

2,992

7,463

2,448

5,322

978

-29,500

4,164

-735

-5,149

2,899

1,715

2,692

1,931

19,390

16

-651

2,650

-989

-1,185

-1,984

-6,141

Cash flows from financing activities
Net proceeds from the issuance of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42,814

0

-6

21,141

-

-

-

-

-

-

-

-

-

-

-

-

Tax payments related to shares withheld for vested restricted stock units

-

-

-

-

-

0

29

0

643

0

0

0

156

-2

0

0

210

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21

21

21

Proceeds from exercise of stock options

4

0

12

0

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

357

783

86

3

19

16

47

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2

2

1

2

2

15

23

21

23

-

-

-

-

Net cash provided by financing activities

4

0

13

0

2

0

74

24,474

-643

0

45,648

0

-156

13,691

0

0

-210

-

-

-

-

42,814

0

-623

21,139

-2

356

781

84

-12

-4

-5

24

-22

-38

49,033

-21

Net decrease in cash and cash equivalents

-4,032

-3,045

-5,420

11,581

-3,710

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Issuance of 2019 bonus awards with stock options in lieu of cash

415

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Asset acquisition costs included in accounts payable and accrued liabilities

-

-

-

-

1,268

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs included in accounts payable and accrued liabilities

179

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

5,169

6,578

1,553

-858

-37,615

48,275

-2,615

-1,139

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,334

-2,491

-1,993

2,259

-2,526

160

-3,717

8,253

-1,551

-11,254

7,903

-4,754

-8,969

-7,884

-11,908

9,313

-8,588

-8,590

-7,836

-9,551

-9,125

39,631

-15,391